logo

Biodelivery Sciences International Inc (BDSI)



Trade BDSI now with
  Date
  Headline
12/20/2017 8:50:28 AM BioDelivery Sciences Appoints Scott Plesha To The Role Of President
10/6/2017 7:03:13 AM BioDelivery Sciences Participates In HHS Round Table Discussion On Pain Management And Opioid Dependence
9/12/2017 8:18:53 AM BioDelivery Sciences Reports Granting Of Market Authorization Transfer By Health Canada For BELBUCA
8/23/2017 7:40:23 AM BioDelivery Sciences President And CEO Mark Sirgo To Retire At Year-End While Continuing As Vice Chairman
7/12/2017 7:33:31 AM BioDelivery Sciences, Purdue Pharma (Canada) Sign Exclusive Agreement For BELBUCA (buprenorphine Buccal Film)
6/21/2017 8:50:02 AM BioDelivery Sciences Enters Agreement With CVS/Caremark For BELBUCA And BUNAVAIL Through 2020
5/2/2017 7:14:02 AM BioDelivery Sciences Unveils Approval Of BUNAVAIL For Induction Of Buprenorphine Treatment For Opioid Dependence
3/17/2017 6:35:46 AM BioDelivery Sciences Q4 Net Loss $15.9 Mln Or $0.29/Shr Vs Income Of $10.2 Mln Or $0.19/Shr Last Year
12/14/2016 7:02:48 AM BioDelivery Sciences Names Peter Ginsberg As VP Of Business Development
12/13/2016 6:57:20 AM BioDelivery Sciences: Phase 2b Trial Of Clonidine Topical Gel Fails To Meet Primary Efficacy Endpoint
12/8/2016 6:10:12 AM BioDelivery Sciences Enters Agreement With Endo Terminating Licensing Of Rights For BELBUCA Buccal Film
11/9/2016 6:04:24 AM BioDelivery Sciences Q3 Net Loss Narrows To $16.0 Mln Or $0.30/shr From $20.4 Mln Or $0.39/shr Last Year
9/19/2016 7:14:18 AM BioDelivery Sciences Secures Three New Managed Care Contracts For BUNAVAIL
8/9/2016 6:14:11 AM BioDelivery Sciences Q2 Total Net Revenue $5.0 Mln, Increase Of 189% Over Last Year
6/6/2016 7:21:25 AM BioDelivery Sciences Announces Presentation Of Data On Impact Of State Formulary Conversion To BUNAVAIL
5/10/2016 7:27:13 AM BioDelivery Sciences Q1 Net Loss $18.7 Mln Or $0.36/shr Vs Loss Of $8.2 Mln Or $0.16/shr Last Year